BCAX - NASDAQ

Bicara Therapeutics Inc. Common Stock

BCAX·NASDAQ

$20.00

+1.8%

HealthcareBiotechnology

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics Inc. is a subsidiary of Biocon Limited.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$1.10B

EPS-2.5200

P/E Ratio-7.94

Earnings Date08/11/2026

bcax

Total Non-Current Liabilities

Last Annual Value

593.00K

3-Year CAGR

91%

5-Year CAGR

47%

10-Year CAGR

21%

Adjust for Inflation

Bicara Therapeutics Inc. Common Stock Competitors Analysis of Total Non-Current Liabilities

BCAX · NASDAQ

Company	Total Non-Current Liabilities	CAGR 3Y	CAGR 5Y	CAGR 10Y
Bicara Therapeutics Inc. Common Stock NASDAQ:BCAX	593.00K	15.1%	N/A	N/A
Fortrea Holdings Inc. NASDAQ:FTRE	1.24B	-12.4%	34.5%	N/A
Phathom Pharmaceuticals, Inc. NASDAQ:PHAT	565.27M	8.1%	41.9%	N/A
Prime Medicine, Inc. NASDAQ:PRME	184.42M	248.5%	111.9%	N/A
EyePoint Pharmaceuticals, Inc. NASDAQ:EYPT	20.86M	-6.6%	-17.7%	14.0%
ProKidney Corp. NASDAQ:PROK	4.04M	-1.1%	30.5%	N/A
Savara Inc. NASDAQ:SVRA	29.91M	4.0%	11.4%	-6.9%
Tango Therapeutics, Inc. NASDAQ:TNGX	30.83M	-33.2%	-23.1%	N/A
Maravai LifeSciences Holdings, Inc. NASDAQ:MRVI	352.95M	-16.7%	-22.7%	N/A
Kura Oncology, Inc. NASDAQ:KURA	447.25M	201.0%	145.8%	50.5%
Septerna, Inc. NASDAQ:SEPN	127.33M	-7.8%	N/A	N/A

Bicara Therapeutics Inc. Common Stock Fair Value Envelope

BCAX · NASDAQ

Our analysis suggests that BCAX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $20, this represents a potential HIDDEN relative to our calculated worth for Bicara Therapeutics Inc. Common Stock.

HIDDEN

Intrinsic Value

Current Price: $20

Related Guides

Blog Categories

Continue your BCAX research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.